{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:25:30Z","timestamp":1789770330242,"version":"4.0.1"},"reference-count":16,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:p>We report a case of therapeutic drug monitoring guided raltegravir use for the prevention of vertical HIV transmission in a premature neonate born to a woman living with perinatally acquired HIV and documented resistance to multiple HIV drugs. Maternal viral load was above 1,000 copies\/ml at delivery. This case demonstrates delayed raltegravir elimination in a neonate born at 33 weeks gestational age and a need for less frequent raltegravir dosing than is used in older infants and children.<\/jats:p>","DOI":"10.3851\/imp3139","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T06:29:04Z","timestamp":1487140144000},"page":"545-549","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic drug Monitoring Guided Raltegravir Dosing for Prevention of Vertical Transmission in a Premature Neonate Born to a Woman Living with Perinatally Acquired HIV"],"prefix":"10.1177","volume":"22","author":[{"given":"Denise","family":"Kreutzwiser","sequence":"first","affiliation":[{"name":"McGill University Health Centre, Chronic Viral Illness Service, Montr\u00e9al, QC, Canada"},{"name":"Toronto General Hospital, University Health Network, Immunodeficiency Clinic, Toronto, ON, Canada"},{"name":"University of Toronto, Leslie Dan Faculty of Pharmacy, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Sheehan","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Chronic Viral Illness Service, Montr\u00e9al, QC, Canada"},{"name":"McGill University Health Centre, Qu\u00e9bec Antiretroviral Therapeutic Drug Monitoring Program, Montr\u00e9al, QC, Canada"},{"name":"Universit\u00e9 de Montr\u00e9al, Facult\u00e9 de Pharmacie, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Dayneka","sequence":"additional","affiliation":[{"name":"Children's Hospital of Eastern Ontario, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Lemire","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Chronic Viral Illness Service, Montr\u00e9al, QC, Canada"},{"name":"McGill University Health Centre, Qu\u00e9bec Antiretroviral Therapeutic Drug Monitoring Program, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Wong","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Chronic Viral Illness Service, Montr\u00e9al, QC, Canada"},{"name":"McGill University Health Centre, Qu\u00e9bec Antiretroviral Therapeutic Drug Monitoring Program, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindy","family":"Samson","sequence":"additional","affiliation":[{"name":"Children's Hospital of Eastern Ontario, Ottawa, ON, Canada"},{"name":"Department of Pediatrics, University of Ottawa, Faculty of Medicine, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Brophy","sequence":"additional","affiliation":[{"name":"Children's Hospital of Eastern Ontario, Ottawa, ON, Canada"},{"name":"Department of Pediatrics, University of Ottawa, Faculty of Medicine, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,8,1]]},"reference":[{"key":"bibr1-IMP3139","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/301763"},{"key":"bibr2-IMP3139","volume-title":"Product monograph","author":"Isentress\u00ae (raltegravir).","year":"2015"},{"key":"bibr3-IMP3139","doi-asserted-by":"publisher","DOI":"10.2174\/138920012800840455"},{"key":"bibr4-IMP3139","doi-asserted-by":"publisher","DOI":"10.1042\/bj1960257"},{"key":"bibr5-IMP3139","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000316"},{"key":"bibr6-IMP3139","unstructured":"IMPAACT P1097. Raltegravir pharmacokinetics and safety in neonates. Protocol Version 2.0 (22 January 2014). (Accessed 29 September 2016.) Available from http:\/\/www.impaactnetwork.org\/studies\/P1097.asp."},{"key":"bibr7-IMP3139","unstructured":"Stanford University HIV Drug Resistance Database. Version 8.1. (Updated 23 September 2016. Accessed 28 September 2016.) Available from https:\/\/hivdb.stanford.edu."},{"key":"bibr8-IMP3139","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001291"},{"key":"bibr9-IMP3139","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342060-00009"},{"key":"bibr10-IMP3139","unstructured":"Letter of Amendment #2 for: IMPAACT P1110. A Phase I trial to evaluate the safety and pharmacokinetics of raltegravir in HIV-1-exposed neonates at high risk of acquiring HIV-1 infection. Letter of Amendment Date: 30 June 2015. (Accessed 28 September 2016.) Available from http:\/\/impaactnetwork.org\/studies\/P1110.asp."},{"key":"bibr11-IMP3139","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06417-11"},{"key":"bibr12-IMP3139","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835a9aeb"},{"key":"bibr13-IMP3139","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01349-13"},{"key":"bibr14-IMP3139","volume-title":"Product monograph","author":"Viramune\u00ae and Viramune XR\u00ae (nevirapine).","year":"2013"},{"key":"bibr15-IMP3139","unstructured":"Liverpool Drug Interactions Group, University of Liverpool. Nevirapine PK fact sheet. Liverpool, United Kingdom. (Updated March 2016. Accessed 30 September 2016.) Available from http:\/\/www.hiv-druginteractions.org."},{"key":"bibr16-IMP3139","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000976"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3139","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:16Z","timestamp":1777380736000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,1]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.3851\/IMP3139"],"URL":"https:\/\/doi.org\/10.3851\/imp3139","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,1]]}}}